Following the recommendations of the SSO (Swiss Society of Ophthalmology), all intra-vitreal injections are performed in a type I operating theater at Vista Alpina.
Intravitreal therapy (injection of Lucentis ® or Eylea ®)
Intravitreal treatment aims at reducing macular oedemas (= water retention in the retina). This occurs in various illnesses, e.g.
wet macular degeneration
diabetic macular oedema
thromboses (= blood clots) of the retina
A small dose of medication is administered into the eye (into the vitreous body) through frequent (often times monthly) injections. This medication dries the macula.
The frequency of injections is custom scaled according to the course of the disease. It is the goal of Vista Alpina Augenzentrum, to administer the least possible injections without the macular oedema recurring.
Determining the optimal injection frequency requires years of respective experience and the necessary medical touch.
Study of Dr. Vandekerckhove, MD: Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
The purpose of this study was to compare the efficacy of intravitreal aflibercept versus ranibizumab for treating therapy-resistant diabetic macular oedema (DME). A 69-year-old man presented with persistent bilateral DME despite previous ranibizumab treatment [...].